NO20062271L - CCI-779 for behandling av mantle celle lymfom - Google Patents

CCI-779 for behandling av mantle celle lymfom

Info

Publication number
NO20062271L
NO20062271L NO20062271A NO20062271A NO20062271L NO 20062271 L NO20062271 L NO 20062271L NO 20062271 A NO20062271 A NO 20062271A NO 20062271 A NO20062271 A NO 20062271A NO 20062271 L NO20062271 L NO 20062271L
Authority
NO
Norway
Prior art keywords
treatment
cell lymphoma
mantle cell
cci
ccl1
Prior art date
Application number
NO20062271A
Other languages
English (en)
Inventor
Thomas E Witzig
Scott H Kaufmann
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590151&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062271(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mayo Foundation filed Critical Mayo Foundation
Publication of NO20062271L publication Critical patent/NO20062271L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Epoxy Compounds (AREA)

Abstract

Anvendelse av rapamycin-42-ester med 3-hydroksy-2-(hydroksymetyl)-2-metylpropionsyre (CC1-779) ved behandling eller inhibering av mantelcellelymfom.
NO20062271A 2003-11-04 2006-05-19 CCI-779 for behandling av mantle celle lymfom NO20062271L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US51732903P 2003-11-04 2003-11-04
PCT/US2004/035900 WO2005046681A1 (en) 2003-11-04 2004-10-28 Cci-779 for treating mantle cell lymphoma

Publications (1)

Publication Number Publication Date
NO20062271L true NO20062271L (no) 2006-07-21

Family

ID=34590151

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062271A NO20062271L (no) 2003-11-04 2006-05-19 CCI-779 for behandling av mantle celle lymfom

Country Status (31)

Country Link
US (2) US20050113403A1 (no)
EP (1) EP1682131B9 (no)
JP (1) JP4856548B2 (no)
KR (1) KR101387988B1 (no)
CN (1) CN1901906B (no)
AR (1) AR046194A1 (no)
AT (1) ATE373477T1 (no)
AU (1) AU2004289213B2 (no)
BR (1) BRPI0415714A (no)
CA (1) CA2543665C (no)
CO (1) CO5690605A2 (no)
CR (1) CR8383A (no)
DE (1) DE602004009098T2 (no)
DK (1) DK1682131T3 (no)
EC (1) ECSP066600A (no)
ES (1) ES2291954T3 (no)
GT (1) GT200400224A (no)
HK (1) HK1088241A1 (no)
IL (2) IL175128A0 (no)
MY (1) MY136436A (no)
NO (1) NO20062271L (no)
PA (1) PA8616601A1 (no)
PE (1) PE20051000A1 (no)
PL (1) PL1682131T3 (no)
PT (1) PT1682131E (no)
RU (1) RU2358731C2 (no)
SA (1) SA04250375B1 (no)
TW (1) TW200517116A (no)
UA (1) UA83697C2 (no)
WO (1) WO2005046681A1 (no)
ZA (1) ZA200603533B (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab
US20080207644A1 (en) * 2006-11-27 2008-08-28 Sonis Stephen T Therapeutic materials and methods
CN104031122B (zh) * 2014-06-23 2016-05-11 常州市肿瘤医院 有关Cyclin D蛋白抑制剂多肽及其应用
CN104017051B (zh) * 2014-06-23 2016-08-17 深圳市华中生物药械有限公司 一种Cyclin D 蛋白抑制剂多肽及其应用
CN104004060B (zh) * 2014-06-23 2016-04-13 重庆医科大学 Cyclin D蛋白抑制剂多肽及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
US6277983B1 (en) * 2000-09-27 2001-08-21 American Home Products Corporation Regioselective synthesis of rapamycin derivatives
TWI256395B (en) 1999-09-29 2006-06-11 Wyeth Corp Regioselective synthesis of rapamycin derivatives
JP2004509898A (ja) * 2000-09-19 2004-04-02 ワイス 水溶性ラパマイシンエステル
TWI286074B (en) * 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
TWI296196B (en) * 2001-04-06 2008-05-01 Wyeth Corp Antineoplastic combinations
US20030008923A1 (en) * 2001-06-01 2003-01-09 Wyeth Antineoplastic combinations
US20020198137A1 (en) * 2001-06-01 2002-12-26 Wyeth Antineoplastic combinations
SG153647A1 (en) 2001-06-01 2009-07-29 Wyeth Corp Antineoplastic combinations
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
PL216224B1 (pl) 2002-02-01 2014-03-31 Ariad Pharmaceuticals Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
DK1553940T3 (da) * 2002-07-30 2008-06-02 Wyeth Corp Patenterale formuleringer indeholdende en rapamycin-hydroxyester
KR20060006058A (ko) * 2003-04-22 2006-01-18 와이어쓰 항신생물성 배합물
TW200524864A (en) 2003-11-10 2005-08-01 Wyeth Corp Sulfonyltetrahydro-3H-benzo(E)indole-8-amine compounds as 5-hydroxytryptamine-6 ligands
AR047988A1 (es) * 2004-03-11 2006-03-15 Wyeth Corp Combinaciones antineoplásicas de cci-779 y rituximab

Also Published As

Publication number Publication date
DE602004009098D1 (de) 2007-10-31
PA8616601A1 (es) 2006-06-02
RU2358731C2 (ru) 2009-06-20
CO5690605A2 (es) 2006-10-31
GT200400224A (es) 2005-06-06
CN1901906A (zh) 2007-01-24
ECSP066600A (es) 2006-10-25
EP1682131B1 (en) 2007-09-19
CR8383A (es) 2006-10-04
WO2005046681A1 (en) 2005-05-26
DE602004009098T2 (de) 2008-06-26
PE20051000A1 (es) 2006-02-03
CA2543665C (en) 2009-07-14
AU2004289213B2 (en) 2010-08-26
UA83697C2 (ru) 2008-08-11
BRPI0415714A (pt) 2006-12-19
CA2543665A1 (en) 2005-05-26
US8507518B2 (en) 2013-08-13
RU2006119451A (ru) 2007-12-20
MY136436A (en) 2008-10-31
PL1682131T3 (pl) 2008-02-29
US20110184010A1 (en) 2011-07-28
ES2291954T3 (es) 2008-03-01
CN1901906B (zh) 2011-11-16
KR20060111559A (ko) 2006-10-27
HK1088241A1 (en) 2006-11-03
US20050113403A1 (en) 2005-05-26
SA04250375B1 (ar) 2007-08-13
EP1682131A1 (en) 2006-07-26
ZA200603533B (en) 2007-07-25
AU2004289213A1 (en) 2005-05-26
DK1682131T3 (da) 2008-01-28
IL175128A0 (en) 2008-04-13
EP1682131B9 (en) 2009-03-25
PT1682131E (pt) 2007-11-08
JP2007510721A (ja) 2007-04-26
IL220080A0 (en) 2012-07-31
TW200517116A (en) 2005-06-01
ATE373477T1 (de) 2007-10-15
JP4856548B2 (ja) 2012-01-18
AR046194A1 (es) 2005-11-30
KR101387988B1 (ko) 2014-04-22

Similar Documents

Publication Publication Date Title
AR031341A1 (es) Uso de cci-779 como agente antineoplastico
NO20054412L (no) Antineoplastiske kombinasjoner
TW200510428A (en) Amorphous rapamycin 42-ester with 3-hydroxy-2-(hydroxymethyl)-2-methylpropionic acid and its pharmaceutical compositions
NO20050836L (no) Oralformuleringer
NO20161348A1 (no) Anvendelse av 40-O-(2-hydroksyetyl)-rapamycin i behandling av faste tumorer i lunger annet enn lymfekreft
NO20062271L (no) CCI-779 for behandling av mantle celle lymfom
ES2421455T3 (es) Uso de derivados de rapamicina en vasculopatías
EA200801309A1 (ru) ВВЕДЕНИЕ ИНГИБИТОРА mTOR ДЛЯ ЛЕЧЕНИЯ ПАЦИЕНТОВ СО ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛЬЮ
ATE305788T1 (de) (s,s)-reboxetin zur behandlung von inkontinenz
PT1292591E (pt) Derivados biciclicos substituidos para o tratamento de crescimento de celula anormal
AR043403A1 (es) Combinaciones antineoplasticas
NO20053483D0 (no) 4-Anilinokinazolinderivater for behandling av unormal cellevekst
PE20080138A1 (es) Procesos para preparar conjugados de polietilen glicol solubles en agua de inmunosupresores macrolidos
AR034071A1 (es) Combinaciones antineoplasicas
GT200600044A (es) Polimorfo cci-779 y su uso
ES2543853T3 (es) Actividad antitumoral del temsirolimus frente al carcinoma papilar de células renales
WO2004070018A3 (en) Vegf-b and pdgf modulation of stem cells
EA200601128A1 (ru) Пиразолопиримидины
AU2003257041A1 (en) Methods for treating ocular inflammation by neutralizing cxcl10 activity
SI1682131T1 (sl) CCI-779 za zdravljenje limfoma plascnih celic
RU98114307A (ru) Способ лечения бактериального вагиноза
FI20031029A0 (fi) Menetelmä ja järjestely pyöreähköjen kappaleden käsittelemiseksi

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application